{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:30:52Z","timestamp":1793255452675,"version":"4.5.0"},"reference-count":8,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"DOI":"10.31744\/einstein_journal\/2025rc1439","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:57:27Z","timestamp":1759751847000},"source":"Crossref","is-referenced-by-count":2,"title":["Raynaud's phenomenon during treatment with lisdexamfetamine: risk of cerebral vasospasm?"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-9983","authenticated-orcid":false,"given":"Rubens","family":"Pitliuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8186-8415","authenticated-orcid":false,"given":"Tatyanny Paula Pinto da Costa Santos","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"2","key":"key20251006115724_B1","first-page":"123","article-title":"A review of raynaud's disease","volume":"113","author":"Temprano","year":"2016","unstructured":"1 Temprano KK. A review of raynaud's disease. Mo Med. 2016;113(2):123-6. Review.","journal-title":"Mo Med"},{"issue":"6","key":"key20251006115724_B2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque","year":"2020","unstructured":"2 Haque A, Hughes M. Raynaud's phenomenon. Clin Med (Lond). 2020; 20(6):580-7.","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"key20251006115724_B3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-015-0354-y","article-title":"Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy","volume":"36","author":"Ermer","year":"2016","unstructured":"3 Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36(5):341-56. Review.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"key20251006115724_B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1590\/0101-60830000000007","article-title":"Lisdexamfetamine dimesylate in the treatment of attention-deficit\/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents","volume":"41","author":"Mattos","year":"2014","unstructured":"4 Mattos P. Lisdexamfetamine dimesylate in the treatment of attention-deficit\/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents. Rev Psiq Cl\u00edn. 2014;41(2):34-9.","journal-title":"Rev Psiq Cl\u00edn"},{"key":"key20251006115724_B5","volume-title":"Dexamphetamine and Raynaud's phenomenon","author":"Bijwerkingencentrum Lareb","year":"2016","unstructured":"5 Bijwerkingencentrum Lareb. Dexamphetamine and Raynaud's phenomenon. Lareb; 2016 [cited 2023 Sep 9]. Available from:: https:\/\/databankws.lareb.nl\/Downloads\/Signals_2016_Dexamphetamine_and_Raynauds_phenomenon.pdf"},{"issue":"1","key":"key20251006115724_B6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1590\/S0482-50042009000100006","article-title":"Fen\u00f4meno de Raynaud","volume":"49","author":"Kayser","year":"2009","unstructured":"6 Kayser C, Corr\u00eaa MJ, Andrade LE. Fen\u00f4meno de Raynaud. Rev Bras Reumatol. 2009;49(1):48-63.","journal-title":"Rev Bras Reumatol"},{"issue":"5","key":"key20251006115724_B7","first-page":"20l02857","article-title":"Rare Side Effects of stimulants: Raynaud's Phenomenon","volume":"23","author":"Gupta","year":"2021","unstructured":"7 Gupta M. Rare Side Effects of stimulants: Raynaud's Phenomenon. Prim Care Companion CNS Disord. 2021;23(5):20l02857.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"5","key":"key20251006115724_B8","first-page":"17l02240","article-title":"Lisdexamfetamine and Secondary Raynaud's Phenomenon [letter]","volume":"20","author":"Gnanavel","year":"2018","unstructured":"8 Gnanavel S. Lisdexamfetamine and Secondary Raynaud's Phenomenon [letter]. Prim Care Companion CNS Disord. 2018;20(5):17l02240.","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:57:28Z","timestamp":1759751848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/raynauds-phenomenon-during-treatment-with-lisdexamfetamine-risk-of-cerebral-vasospasm\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":8,"alternative-id":["10.31744\/einstein_journal\/2025RC1439"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025rc1439","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eRC1439"}}